# Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

> **NCT02433236** · PHASE2 · WITHDRAWN · sponsor: **Rigel Pharmaceuticals**

## Conditions studied

- IGA Nephropathy

## Interventions

- **DRUG:** Fostamatinib Disodium tablet 100 mg
- **DRUG:** Fostamatinib Disodium tablet 150 mg

## Key facts

- **NCT ID:** NCT02433236
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-09
- **Primary completion:** 2015-09
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn prior to enrollment of first subject
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02433236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02433236, "Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02433236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*